Intellectual property issues of immune checkpoint inhibitors

被引：8

作者：

Storz, Ulrich ^{[1
,2
]}

机构：

[1] Michalski, Dusseldorf, Germany

[2] Huttermann Patent Attorneys, Dusseldorf, Germany

来源：

MABS | 2016年 / 8卷 / 01期

关键词：

antibody; CTLA4; Immune checkpoint inhibitors; Keytruda; Opdivo; patent; PD1; PD-L1; Yervoy; B7; FAMILY; CTLA-4; ANTIBODIES; CP-675,206; MELANOMA; THERAPY; MEMBER; B7-H1; PD-1;

D O I：

10.1080/19420862.2015.1107688

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.

引用

页码：10 / 26

页数：17

共 50 条

[31] Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
Hamada, Kazuyuki
Tsunoda, Takuya
Yoshimura, Kiyoshi
LIFE-BASEL, 2022, 12 (08):
[32] Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
Ring, Kari L.
Pakish, Janelle
Jazaeri, Amir A.
CANCER JOURNAL, 2016, 22 (02) : 101 - 107
[33] Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, Randy F.
Luke, Jason J.
PHARMACOLOGICAL RESEARCH, 2017, 120 : 1 - 9
[34] Immune checkpoint inhibitors to treat cutaneous malignancies
Barrios, Dulce M.
Do, Mytrang H.
Phillips, Gregory S.
Postow, Michael A.
Akaike, Tomoko
Nghiem, Paul
Lacouture, Mario E.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1239 - 1253
[35] Cutaneous manifestations associated with immune checkpoint inhibitors
Watanabe, Tomoya
Yamaguchi, Yukie
FRONTIERS IN IMMUNOLOGY, 2023, 14
[36] Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist
Taritsa, Iulianna
Choi, Jennifer N.
CURRENT DERMATOLOGY REPORTS, 2023, 12 (04) : 225 - 232
[37] Common endocrine system adverse events associated with immune checkpoint inhibitors☆
Li, Ying
Zhao, Junfeng
Wang, Yue
Xu, Yali
Li, Ruyue
Zhao, Ying
Dong, Xue
Yao, Xiujing
Li, Yintao
CANCER PATHOGENESIS AND THERAPY, 2024, 2 (03): : 164 - 172
[38] Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
Yu, Caberry W.
Yau, Matthew
Mezey, Natalie
Joarder, Ishraq
Micieli, Jonathan A.
EYE AND BRAIN, 2020, 12 : 139 - 167
[39] Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians
Deligiorgi, Maria V.
Panayiotidis, Mihalis I.
Trafalis, Dimitrios T.
IMMUNOTHERAPY, 2020, 12 (07) : 481 - 510
[40] The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Gong, Jun
Chehrazi-Raffle, Alexander
Placencio-Hickok, Veronica
Guan, Michelle
Hendifar, Andrew
Salgia, Ravi
CLINICAL AND TRANSLATIONAL MEDICINE, 2019, 8

← 1 2 3 4 5 →